혈장 분획 시장 : 제품별, 부문별, 용도별, 최종사용자별, 지역별(2025-2033년)

The global plasma fractionation market size reached USD 26.4 Billion in 2024. Looking forward, the market is expected to reach USD 41.4 Billion by 2033, exhibiting a growth rate (CAGR) of 4.86% during 2025-2033. The rising prevalence of chronic diseases, technological advancements, and the increasing investment in healthcare are some of the major factors driving the market growth.

Plasma fractionation refers to the downstream processing of donated plasma into life-saving therapies and medicinal products. It breaks plasma into individual proteins or plasma fractions using mechanical separation methods, such as centrifugation, depth filtration, precipitation, and chromatography. Nowadays, several modern fractionation processes use alcohol concentrations, time, temperature, and pH to extract specific therapeutic proteins. Moreover, increasing technology complexity over the years and the introduction of in-process viral reduction treatments have resulted in the development of new protein therapeutics and improvement in product purity and quality.

Plasma Fractionation Market Trends:

Protein products fractionated from human plasma are an essential class of therapeutics widely used to prevent, manage, and treat life-threatening conditions, such as infections, congenital deficiencies, rare blood disorders, immunologic disorders, and autoimmune disorders. A significant rise in the prevalence of these conditions among a significant part of the population globally represents one of the key factors impelling the market growth. In addition, manufacturers are developing plasma fractionation with additional safety features due to the implementation of stringent regulations and standard controls and settings by governing agencies of numerous countries on quality assurance of biological products. Apart from this, market players are financing research and development (R&D) activities to launch advancement in plasma production technology to improve product efficacy and enhance recovery of immunoglobulin G (IgG) to isolate new plasma proteins. Furthermore, they are focusing on developing affordable viral inactivation and processing technologies that allow utilization of local plasma resources safely. This, in confluence with the escalating need to improve yield, maintain process economics, and manage increasing regulatory requirements, is anticipated to provide a favorable market outlook in the coming years.

Key Market Segmentation:

Breakup by Product:

• Immunoglobulins
• Albumin
• Coagulation factor VIII
• Coagulation factor IX

Breakup by Sector:

• Private Sector
• Public Sector

Breakup by Application:

• Neurology
• Immunology
• Hematology
• Other Applications

Breakup by End User:

• Hospitals and Clinics
• Clinical Research Laboratories
• Academic Institutes

Breakup by Region:

• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being ADMA Biologics, Bio Products Laboratory Ltd., Boccard, Grifols, S.A., Hemarus Therapeutics Limited, Intas Pharmaceuticals Limited, LFB S.A., Merck Group, Octapharma AG, PlasmaGen BioSciences Pvt. Ltd., SK Plasma Co. Ltd. and Virchow Biotech Private Limited.

Key Questions Answered in This Report

• 1.What was the size of the global plasma fractionation market in 2024?
• 2.What is the expected growth rate of the global plasma fractionation market during 2025-2033?
• 3.What has been the impact of COVID-19 on the global plasma fractionation market?
• 4.What are the key factors driving the global plasma fractionation market?
• 5.What is the breakup of the global plasma fractionation market based on the product?
• 6.What is the breakup of the global plasma fractionation market based on the sector?
• 7.What is the breakup of the global plasma fractionation market based on the application?
• 8.What is the breakup of the global plasma fractionation market based on the end user?
• 9.What are the key regions in the global plasma fractionation market?
• 10.Who are the key players/companies in the global plasma fractionation market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Plasma Fractionation Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Product

• 6.1 Immunoglobulins
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Albumin
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Coagulation factor VIII
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Coagulation factor IX
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Sector

• 7.1 Private Sector
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Public Sector
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Application

• 8.1 Neurology
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Immunology
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Hematology
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Other Applications
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by End User

• 9.1 Hospitals and Clinics
  • 9.1.1 Market Trends
  • 9.1.2 Market Forecast
• 9.2 Clinical Research Laboratories
  • 9.2.1 Market Trends
  • 9.2.2 Market Forecast
• 9.3 Academic Institutes
  • 9.3.1 Market Trends
  • 9.3.2 Market Forecast

10 Market Breakup by Region

• 10.1 North America
  • 10.1.1 United States
    • 10.1.1.1 Market Trends
    • 10.1.1.2 Market Forecast
  • 10.1.2 Canada
    • 10.1.2.1 Market Trends
    • 10.1.2.2 Market Forecast
• 10.2 Asia-Pacific
  • 10.2.1 China
    • 10.2.1.1 Market Trends
    • 10.2.1.2 Market Forecast
  • 10.2.2 Japan
    • 10.2.2.1 Market Trends
    • 10.2.2.2 Market Forecast
  • 10.2.3 India
    • 10.2.3.1 Market Trends
    • 10.2.3.2 Market Forecast
  • 10.2.4 South Korea
    • 10.2.4.1 Market Trends
    • 10.2.4.2 Market Forecast
  • 10.2.5 Australia
    • 10.2.5.1 Market Trends
    • 10.2.5.2 Market Forecast
  • 10.2.6 Indonesia
    • 10.2.6.1 Market Trends
    • 10.2.6.2 Market Forecast
  • 10.2.7 Others
    • 10.2.7.1 Market Trends
    • 10.2.7.2 Market Forecast
• 10.3 Europe
  • 10.3.1 Germany
    • 10.3.1.1 Market Trends
    • 10.3.1.2 Market Forecast
  • 10.3.2 France
    • 10.3.2.1 Market Trends
    • 10.3.2.2 Market Forecast
  • 10.3.3 United Kingdom
    • 10.3.3.1 Market Trends
    • 10.3.3.2 Market Forecast
  • 10.3.4 Italy
    • 10.3.4.1 Market Trends
    • 10.3.4.2 Market Forecast
  • 10.3.5 Spain
    • 10.3.5.1 Market Trends
    • 10.3.5.2 Market Forecast
  • 10.3.6 Russia
    • 10.3.6.1 Market Trends
    • 10.3.6.2 Market Forecast
  • 10.3.7 Others
    • 10.3.7.1 Market Trends
    • 10.3.7.2 Market Forecast
• 10.4 Latin America
  • 10.4.1 Brazil
    • 10.4.1.1 Market Trends
    • 10.4.1.2 Market Forecast
  • 10.4.2 Mexico
    • 10.4.2.1 Market Trends
    • 10.4.2.2 Market Forecast
  • 10.4.3 Others
    • 10.4.3.1 Market Trends
    • 10.4.3.2 Market Forecast
• 10.5 Middle East and Africa
  • 10.5.1 Market Trends
  • 10.5.2 Market Breakup by Country
  • 10.5.3 Market Forecast

11 SWOT Analysis

• 11.1 Overview
• 11.2 Strengths
• 11.3 Weaknesses
• 11.4 Opportunities
• 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

• 13.1 Overview
• 13.2 Bargaining Power of Buyers
• 13.3 Bargaining Power of Suppliers
• 13.4 Degree of Competition
• 13.5 Threat of New Entrants
• 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

• 15.1 Market Structure
• 15.2 Key Players
• 15.3 Profiles of Key Players
  • 15.3.1 ADMA Biologics
    • 15.3.1.1 Company Overview
    • 15.3.1.2 Product Portfolio
    • 15.3.1.3 Financials
  • 15.3.2 Bio Products Laboratory Ltd.
    • 15.3.2.1 Company Overview
    • 15.3.2.2 Product Portfolio
  • 15.3.3 Boccard
    • 15.3.3.1 Company Overview
    • 15.3.3.2 Product Portfolio
  • 15.3.4 Grifols, S.A.
    • 15.3.4.1 Company Overview
    • 15.3.4.2 Product Portfolio
    • 15.3.4.3 Financials
    • 15.3.4.4 SWOT Analysis
  • 15.3.5 Hemarus Therapeutics Limited
    • 15.3.5.1 Company Overview
    • 15.3.5.2 Product Portfolio
  • 15.3.6 Intas Pharmaceuticals Limited
    • 15.3.6.1 Company Overview
    • 15.3.6.2 Product Portfolio
  • 15.3.7 LFB S.A.
    • 15.3.7.1 Company Overview
    • 15.3.7.2 Product Portfolio
  • 15.3.8 Merck Group
    • 15.3.8.1 Company Overview
    • 15.3.8.2 Product Portfolio
    • 15.3.8.3 Financials
    • 15.3.8.4 SWOT Analysis
  • 15.3.9 Octapharma AG
    • 15.3.9.1 Company Overview
    • 15.3.9.2 Product Portfolio
    • 15.3.9.3 SWOT Analysis
  • 15.3.10 PlasmaGen BioSciences Pvt. Ltd.
    • 15.3.10.1 Company Overview
    • 15.3.10.2 Product Portfolio
  • 15.3.11 SK Plasma Co. Ltd.
    • 15.3.11.1 Company Overview
    • 15.3.11.2 Product Portfolio
  • 15.3.12 Virchow Biotech Private Limited
    • 15.3.12.1 Company Overview
    • 15.3.12.2 Product Portfolio